Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors

BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon but can be potentially fatal, and its true...

Full description

Bibliographic Details
Main Authors: María Torrente, Mariola Blanco, Fabio Franco, Yago Garitaonaindia, Virginia Calvo, Ana Collazo-Lorduy, Lourdes Gutiérrez, Juan Cristóbal Sánchez, Aranzazu González-del-Alba, Roberto Hernández, Miriam Méndez, Blanca Cantos, Beatriz Núñez, Pedro A. C. Sousa, Mariano Provencio
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
cardiovascular event
immune checkpoint inhibitors
myocarditis
cardiotoxicity
risk factors
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.1062858/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.1062858/full

Similar Items